Company
Actithera
- Biotech
- Founded:
- 2021
- Headquarters:
- Oslo, Norway
- Offices:
- Cambridge
Description
Actithera develops precisely targeted radioligand therapies by linking radioactive isotopes to designed molecules, producing radiotherapeutics that deliver sustained tumor radiation while minimizing healthy-tissue exposure for cancer patients.
Related
Betaglue® TherapeuticsBetaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision…
PhotocurePhotocure delivers precision diagnostics for bladder cancer, offering products and solutions that provide physicians with timely…
CollimateHealthCollimateHealth develops microbeam radiation systems that deliver arrays of extremely narrow radiation beams to treat tumors while sparing…
ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…
ElektaElekta develops radiotherapy, brachytherapy and imaging systems for precision radiation medicine used by hospitals and cancer centres to…
NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
NeoPhoreNeoPhore develops small-molecule cancer therapeutics that briefly inhibit DNA mismatch repair, shifting MMR-proficient tumors toward an…